BeyondSpring Business Summary

BeyondSpring Inc. (BYSI) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, research collaborations, and equity financing, as it has not yet transitioned to product-based commercial sales. The company operates through two primary business segments: the Plinabulin pipeline and the Targeted Protein Degradation (TPD) platform, the latter of which is managed through its subsidiary, SEED Therapeutics. Its flagship asset, Plinabulin, is a first-in-class selective immunomodulating microtubule-binding agent (SIMBA) currently in late-stage clinical development for the treatment of non-small cell lung cancer (NSCLC) and the prevention of chemotherapy-induced neutropenia (CIN). Direct competitors include Plus Therapeutics, X4 Pharmaceuticals, and Prelude Therapeutics; BeyondSpring differentiates itself by leveraging Plinabulin’s dual-action mechanism, which provides both direct anti-cancer benefits and immune system modulation by promoting dendritic cell maturation. The company was co-founded by Dr. Lan Huang and Linqing Jia, with Dr. Huang serving as Chairman and CEO. Dr. Huang’s pedigree includes over 20 years of entrepreneurial experience in the U.S. and Chinese biotech sectors, having previously founded Wanchun Biotech and co-founded Paramax International. The leadership team is further strengthened by Chief Technology and R&D Officer Dr. June Lu, who joined in 2024 from Novartis and Endocyte, and SVP of Development Dr. John Mao, a veteran of Cytokinetics and Foresee Pharmaceuticals. BeyondSpring’s board of directors includes notable figures such as Patrick Fabbio, CFO of Rafael Holdings, and the company maintains high-profile strategic collaborations with Eli Lilly and Eisai through its SEED Therapeutics subsidiary. Major institutional and strategic support has historically been provided by investors such as Decheng Capital and Vanguard Fiduciary Trust.